![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the...
– Results were simultaneously presented today in a late breaker at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) in Washington, D.C. Silence Therapeutics plc...
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of...
Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 Silence Therapeutics plc (Nasdaq: SLN), a leader in the...
– Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 – SLN124 phase 1 study in thalassemia now fully enrolled;...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the...
Mark Rothera steps down as President and CEO Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering...
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner...
Data to be presented by Professor of Cardiovascular Medicine at the Cleveland Clinic, Steven Nissen, MD, on Sunday April 3, 2022 Silence on-track to report topline data from the SLN360 phase 1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions